# EDGAR Filing Document

**Accession Number:** 0001615982
**File Stem:** 0001231919-25-000176
**Filing Date:** 2025-8
**Character Count:** 21499
**Document Hash:** f365af5a047efdad543c398df48d482d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001231919-25-000176.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001231919-25-000176

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VR Adviser, LLC
- **CENTRAL INDEX KEY:** 0001615982

**ORGANIZATION NAME:**
- **EIN:** 464814731
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-20281
- **FILM NUMBER:** 251282105

**BUSINESS ADDRESS:**
- **STREET 1:** 7 BRYANT PARK
- **STREET 2:** 23RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 650-475-3734

**MAIL ADDRESS:**
- **STREET 1:** 7 BRYANT PARK
- **STREET 2:** 23RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001615982

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** VR Adviser, LLC

**Address:** 7 Bryant Park, New York, NY 10018

**Telephone number:** 212-444-4100

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-20281

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                   | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                                                            | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| ARCA biopharma, Inc.             | 687604108 | 08/22/2024     | To approve, on an advisory basis, certain compensation arrangements for ARCA named executive  officers that are based on or otherwise relate to the Merger;                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 866375           |                0 | FOR         | 866375.000000                            | FOR                         |  |
| KalVista Pharmaceuticals, Inc.   | 483497103 | 10/03/2024     | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      6.24973e+06 |                0 | FOR         | 6249731.000000                           | FOR                         |  |
| Dianthus Therapeutics, Inc.      | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers; and                                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |      1.74437e+06 |                0 | FOR         | 1744373.000000                           | FOR                         |  |
| Spyre Therapeutics, Inc.         | 00773J202 | 05/29/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Dyne Therapeutics, Inc.          | 26818M108 | 05/30/2025     | To vote, on an advisory basis, to approve the compensation of our named executive officers.                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      2.17391e+06 |                0 | FOR         | 2173913.000000                           | FOR                         |  |
| Dyne Therapeutics, Inc.          | 26818M108 | 05/30/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      2.17391e+06 |                0 | ONE YEAR    | 2173913.000000                           | FOR                         |  |
| Oruka Therapeutics, Inc.         | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Oruka Therapeutics, Inc.         | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Cogent Biosciences, Inc.         | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      5.68441e+06 |                0 | FOR         | 5684411.000000                           | FOR                         |  |
| GlycoMimetics, Inc.              | G2545C104 | 06/05/2025     | Approve, on an advisory basis, certain compensation arrangements for GlycoMimetics' named executive officers that are based on or otherwise relate to the Merger.                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |      3e+06       |                0 | FOR         | 3000000.000000                           | FOR                         |  |
| GlycoMimetics, Inc.              | G2545C104 | 06/05/2025     | Approve, on an advisory basis, the compensation of GlycoMimetics' named executive officers.                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      3e+06       |                0 | FOR         | 3000000.000000                           | FOR                         |  |
| Savara Inc.                      | 805111101 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executives.                                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      3.46755e+06 |                0 | FOR         | 3467547.000000                           | FOR                         |  |
| Savara Inc.                      | 805111101 | 06/05/2025     | To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executives.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      3.46755e+06 |                0 | ONE YEAR    | 3467547.000000                           | FOR                         |  |
| Abivax SA                        | 00370M103 | 06/06/2025     | Approve Compensation of Marc de Garidel, Acting Chairman of the Board and CEO                                                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      1.34578e+06 |                0 | FOR         | 1345780.000000                           | FOR                         |  |
| Abivax SA                        | 00370M103 | 06/06/2025     | Approve Compensation of Sylvie Gregoire, Chairwoman of the Board                                                                                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |      1.34578e+06 |                0 | FOR         | 1345780.000000                           | FOR                         |  |
| Applied Therapeutics, Inc.       | 03828A101 | 06/09/2025     | To approve (on a non-binding advisory basis) the compensation of our named executive officers as described in the accompanying materials.                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      5.36042e+06 |                0 | FOR         | 5360425.000000                           | FOR                         |  |
| Applied Therapeutics, Inc.       | 03828A101 | 06/09/2025     | To approve (on a non-binding advisory basis) the frequency of an advisory vote on the compensation of our named executive officers in future years.                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      5.36042e+06 |                0 | ONE YEAR    | 5360425.000000                           | FOR                         |  |
| Astria Therapeutics, Inc.        | 04635X102 | 06/11/2025     | The approval, by non-binding advisory vote, of our executive compensation.                                                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      2.45735e+06 |                0 | FOR         | 2457348.000000                           | FOR                         |  |
| DBV Technologies SA              | 23306J309 | 06/11/2025     | Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2024, to Mr. Michel de Rosen, Chairman of the Board of Directors                                                                                         | SECTION 14A SAY-ON-PAY VOTES |  68701           |                0 | FOR         | 68701.000000                             | FOR                         |  |
| DBV Technologies SA              | 23306J309 | 06/11/2025     | Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2024, to Mr. Daniel Tasse, Chief Executive Officer                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  68701           |                0 | FOR         | 68701.000000                             | FOR                         |  |
| DBV Technologies SA              | 23306J309 | 06/11/2025     | Advisory opinion on the compensation of named executive officers other than the Chief Executive Officer                                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |  68701           |                0 | FOR         | 68701.000000                             | FOR                         |  |
| Ocular Therapeutix, Inc.         | 67576A100 | 06/11/2025     | To approve an advisory vote on named executive officer compensation.                                                                                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      1.27625e+07 |                0 | FOR         | 12762462.000000                          | FOR                         |  |
| Tenax Therapeutics, Inc.         | 88032L605 | 06/11/2025     | Approval, on an advisory basis, of Tenax Therapeutics, Inc.'s 2024 named executive officer compensation.                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 208333           |                0 | FOR         | 208333.000000                            | FOR                         |  |
| Tenax Therapeutics, Inc.         | 88032L605 | 06/11/2025     | Approval, on an advisory basis, on the frequency of future advisory votes on named executive officer compensation.                                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 208333           |                0 | TWO YEARS   | 208333.000000                            | FOR                         |  |
| Trevi Therapeutics, Inc.         | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |  58999           |                0 | FOR         | 58999.000000                             | FOR                         |  |
| Trevi Therapeutics, Inc.         | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |  58999           |                0 | ONE YEAR    | 58999.000000                             | FOR                         |  |
| Cullinan Therapeutics, Inc.      | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, to approve our named executive officer compensation.                                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |      1.37996e+06 |                0 | FOR         | 1379965.000000                           | FOR                         |  |
| Cullinan Therapeutics, Inc.      | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer compensation.                                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      1.37996e+06 |                0 | ONE YEAR    | 1379965.000000                           | FOR                         |  |
| Mersana Therapeutics, Inc.       | 59045L106 | 06/12/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      2.53944e+06 |                0 | FOR         | 2539442.000000                           | FOR                         |  |
| Solid Biosciences Inc.           | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      1.4802e+06  |                0 | FOR         | 1480202.000000                           | FOR                         |  |
| Apogee Therapeutics, Inc.        | 03770N101 | 06/17/2025     | Vote on the frequency of future advisory votes to approve our named executive officers compensation.                                                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      1.75e+06    |                0 | ONE YEAR    | 1750000.000000                           | FOR                         |  |
| Cidara Therapeutics, Inc.        | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 657548           |                0 | FOR         | 657548.000000                            | FOR                         |  |
| Viridian Therapeutics, Inc.      | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      3.88271e+06 |                0 | FOR         | 3882709.000000                           | FOR                         |  |
| Praxis Precision Medicines, Inc. | 74006W207 | 06/26/2025     | To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. | SECTION 14A SAY-ON-PAY VOTES | 244858           |                0 | FOR         | 244858.000000                            | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** VR Adviser, LLC

**By (Signature):** Sherman G. Souther

**By (Printed Signature):** Sherman G. Souther

**By (Title):** Authorized Signatory

**Date:** 07/21/2025